1. Scrip
  2. >>Focus On Asia
  3. >>Japan

MSD To Launch Rotavirus Vaccine Rotateq In Japan

Merck & Co. subsidiary Merck Sharp & Dohme Ltd. announced on July 13 that it will launch Rotateq as an oral vaccine against rotavirus gastroenteritis, a condition seen in children, on July 20.

Merck & Co. subsidiaryMerck Sharp & Dohme Ltd.announced on July 13 that it will launch Rotateq as an oral vaccine against rotavirus gastroenteritis, a condition seen in children, on July 20. Most children who suffer from the rotavirus are infected by the illness by the age of 5, experiencing diarrhea, vomiting, and fever, but complications can also lead to dehydration, cramps, and even encephalitis. Currently, only symptomatic treatment exists for the illness, but MSD aims to spread prevention through vaccination. Rotavirus has many serotypes, but 90% of cases are caused by G1P(8), G2P(4), G3P(8), G4P(8), or (G9P(8). The vaccine targets these serotypes with a 100% efficacy against severe rotavirus gastroenteritis. (Click Here For More – Japanese Language)

“MSD: Rotavirus Vaccine Rotateq On Sale From July 20” mixonline.jp 7/12/2012

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Japan

Taiho’s Oral, Mutation-Agnostic DMD Candidate Misses Phase III Endpoint

 
• By Lisa Takagi

The oral, twice-daily candidate was expected to control decline in motor function in DMD patients regardless of their gene mutations.

Beyond AI Hype: Tokyo-1’s Real Answer On How To Innovate Pharma R&D

 
• By Lisa Takagi

Bringing supercomputing power to bear on large-scale calculations for pharma R&D, Tokyo-based Xeureka explains the practical use of AI to empower innovation beyond the hype.

Can Japan’s Richest Person Save Cell Therapy’s Future?

 
• By Lisa Takagi

With financial help from the founder of Uniqlo, Japan’s leading facility for induced pluripotent stem cells is aiming to automate production to slash costs and kick-start R&D in the field.

Citeline Japan Awards 2025 - Enter Now!

 
• By Ian Haydock and Lisa Takagi

The 14 July deadline for the Citeline Japan Awards 2025 in Tokyo is approaching fast, so here's a reminder to take a look at the categories and criteria and be sure to get those submissions in by this date. Sponsorship opportunities and tables for the event are also available.

More from Focus On Asia

Taiho’s Oral, Mutation-Agnostic DMD Candidate Misses Phase III Endpoint

 
• By Lisa Takagi

The oral, twice-daily candidate was expected to control decline in motor function in DMD patients regardless of their gene mutations.

Wave of Biopharma Licensing Deals in India: ‘The Model Is Working’

 
• By Anju Ghangurde

From vonoprazan and inclisiran to nirsevimab, big pharma has licensed several products to Indian firms as have other biopharma players. Experts discuss the intricacies of such licensing deals amid signs of more action in store and whether geopolitics could dull partnering with Chinese firms.

Beyond AI Hype: Tokyo-1’s Real Answer On How To Innovate Pharma R&D

 
• By Lisa Takagi

Bringing supercomputing power to bear on large-scale calculations for pharma R&D, Tokyo-based Xeureka explains the practical use of AI to empower innovation beyond the hype.